{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-040004","form_type":"8-K","ticker":"RLMD","cik":"0001553643","company_name":"RELMADA THERAPEUTICS, INC.","filed_at":"2023-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.365619+00:00","generated_at":"2026-06-15T01:07:53.137054+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Relmada provides Phase 3 update for REL-1017 in MDD; cash $132.4M","bullets":["Cash and equivalents $132.4M as of 3/31/23; ~30.1M common shares outstanding (45.6M as-converted).","Reliance I and III did not meet primary endpoints; post-hoc analysis with removal of two sites showed -4.1 MADRS difference (p=0.02).","Key trial improvements: require medical records to verify depression, limit patients per site, simplify assessments.","Upcoming milestones: complete Reliance II (adjunctive) in 1H 2024; initiate additional Phase 3 adjunctive trial mid-2023, completion 2H 2024.","No serious treatment-related TEAEs, no abuse potential; safety profile consistent across studies."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-040004","json":"https://secwatch.observer/filing/0001213900-23-040004.json","markdown":"https://secwatch.observer/filing/0001213900-23-040004.md","text":"https://secwatch.observer/filing/0001213900-23-040004.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1553643/000121390023040004/0001213900-23-040004-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1553643/000121390023040004/ea178627-8k_relmada.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T01:07:53.137054+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}